Compare ICFI & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICFI | ANIP |
|---|---|---|
| Founded | 1969 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2006 | 1999 |
| Metric | ICFI | ANIP |
|---|---|---|
| Price | $79.67 | $76.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $99.25 | ★ $107.33 |
| AVG Volume (30 Days) | 121.6K | ★ 309.9K |
| Earning Date | 04-03-2026 | 03-26-2026 |
| Dividend Yield | ★ 0.75% | N/A |
| EPS Growth | ★ 33.79 | N/A |
| EPS | ★ 4.01 | 2.15 |
| Revenue | ★ $1,229,162,000.00 | $206,547,000.00 |
| Revenue This Year | N/A | $44.10 |
| Revenue Next Year | $2.52 | $13.18 |
| P/E Ratio | ★ $18.74 | $35.49 |
| Revenue Growth | ★ 3.72 | 2.47 |
| 52 Week Low | $72.03 | $56.71 |
| 52 Week High | $101.71 | $99.50 |
| Indicator | ICFI | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 42.46 | 43.96 |
| Support Level | $74.24 | $75.20 |
| Resistance Level | $88.80 | $84.47 |
| Average True Range (ATR) | 3.53 | 2.52 |
| MACD | -0.43 | -0.15 |
| Stochastic Oscillator | 40.15 | 39.91 |
ICF International Inc provides professional services and technology-based solutions to government and commercial clients, including management, marketing, technology, and policy consulting and implementation services. Its services support clients that operate in four key markets that include Energy, Environment, Infrastructure and Disaster Recovery; Health and Social Programs and Security and Other Civilian & Commercial. The Company's majority clients are United States federal government departments and agencies. It operates in a single segment, which is providing professional services.
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.